Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study

Anne-Mette B Bjørn¹
Rikke B Nielsen¹
Mette Nørgaard¹
Ellen A Nohr²
Vera Ehrenstein¹
¹Department of Clinical Epidemiology,
²Section for Epidemiology,
Department of Public Health, Aarhus University Hospital, Aarhus, Denmark

Background: The purpose of this nested case-control study in Denmark was to study the association between use of corticosteroids and risk of miscarriage.

Methods: We identified prescriptions for corticosteroids before the miscarriage/index date. We estimated odds ratios (ORs) for miscarriage and for early (<13 weeks) and late (13–21 weeks) miscarriage adjusting for age, history of diabetes and epilepsy, and nonsteroidal anti-inflammatory drug use.

Results: We identified 10,974 women with miscarriage and 109,740 controls. Prevalence of inhaled corticosteroid use within 60 days before the index date was 1.3% among the cases and 1.0% among the controls (OR = 1.20; 95% confidence interval [CI] 1.01–1.44). Prevalence of oral corticosteroid use within 60 days before the index date was 0.3% for both cases and controls (OR = 0.78; 95% CI 0.53–1.15). For inhaled and oral corticosteroids, the ORs of early miscarriage were 1.22 (95% CI 1.01–1.49) and 0.81 (95% CI 0.55–1.20), respectively.

Conclusion: Use of inhaled corticosteroids was associated with a slightly increased risk of early miscarriage, but explanations alternative to causal ones were possible.

Keywords: case-control study, corticosteroid hormones, epidemiology, miscarriage

Introduction
Corticosteroid hormones are potent substances that influence the functioning of most cells in the body,¹ and are used in women of childbearing age² to treat asthma, rheumatoid arthritis, eczema, and inflammatory bowel disease.⁴⁻⁵ In Denmark, an estimated 1.7% of women who give birth use inhaled or oral corticosteroids during early pregnancy.⁶

Miscarriage is the most common adverse event of early pregnancy, occurring in approximately 20% of pregnancies.⁷ Previously, four studies have examined corticosteroid use in pregnancies ending in miscarriage, with numbers of pregnancies ranging from 313⁸ to 281,019.⁹ All of the studies,⁸⁻¹⁰ except one,¹¹ reported an increased risk of miscarriage among women with corticosteroid intake in early pregnancy, with risk ratios ranging from 1.01 (95% confidence interval [CI] 0.48–2.11)¹¹ to 1.66 (95% CI 1.12–2.48).¹⁰ Most published studies were conducted on small samples and not population-based.⁸⁻¹⁰¹¹ Potential confounding by age, smoking, and body mass index could be controlled in only one study.⁸ Also, no study accounted for gestational age at the time of miscarriage, although this information could reveal potential mechanisms behind the putative association.

We conducted a large population-based nested case-control study to examine the relationship between use of corticosteroids and risk of miscarriage. Further, we...
examined whether the association differed for early and late miscarriage.

Materials and methods
Study population and duration
The population of this case-control study stemmed from northern Denmark, which is a well-defined geographic and administrative region with a population of about 1.8 million people or 3% of the total Danish population. Approximately 23,500 births are registered each year in the region. The study period extended from January 1, 1997 to December 31, 2009. Denmark’s tax-funded health care system ensures equal access to health services and partial reimbursement of most prescription drugs. The unique ten-digit personal identifier (CPR number) assigned to Danish residents at birth or upon immigration by the civil registration system encodes date of birth and gender, and is used in all public records, allowing for unambiguous record linkage across data from different registries.

Cases
Cases were women with a first-time miscarriage before the 22nd gestational week and no record of previous delivery. Cases were identified in the Danish National Registry of Patients (DNRP), which tracks admissions to all Danish somatic hospitals since 1977, including diagnoses and procedures; from 1995 onwards, information on outpatient visits has been included. Diagnoses are coded by doctors at discharge, using the International Classification of Diseases, Eighth Revision (ICD-8) before 1994 and Tenth Revision (ICD-10) thereafter. Gestational age at miscarriage has been reported to the DNRP since 1997 and is registered at diagnosis. Gestational age in Denmark is estimated mainly on the basis of ultrasound examination. The index date for the cases was the date of an inpatient or outpatient hospital visit with a diagnosis of miscarriage. We further divided miscarriage into early miscarriage as occurring in the first trimester (up to 12 completed gestational weeks) and late miscarriage as occurring in the second trimester (from gestational week 13 until gestational week 22).

Controls
Controls were women without a history of miscarriage, delivering their first live newborn. To identify controls, we used the Danish Medical Birth Registry, which has tracked all births in Denmark since 1973. For each case, we sampled 10 controls from women whose estimated date of conception (date of delivery minus recorded gestational length plus 14 days) was in the same calendar year as that of the case. The index date for controls was the date on which the fetus had the same gestational age as the fetus of the calendar-year matched case woman at the date of miscarriage.

Use of corticosteroids
We used the Aarhus University Prescription Database to identify prescriptions for inhaled and oral corticosteroids filled by cases and controls before the index date. This database tracks prescriptions of reimbursed drugs sold at community pharmacies in northern Denmark. Inhaled and oral corticosteroids, which are available by prescription only, are eligible for general reimbursement in Denmark and thus generate records in the database. For all relevant prescriptions filled by the women in our study, we noted date of dispensation and type of drug, coded according to the Anatomical Therapeutic Chemical classification system. In some areas of the region, data on dispensations were available starting in 1998. We restricted our sample to women whose prescriptions, based on their place of residence, were expected to be recorded in the database for a minimum of one year before the index date.

Use was defined as a record of at least one relevant prescription. We defined the following categories of inhaled or oral corticosteroid users according to the recency of their last prescription relative to the index date: current users, with the most recent prescription filled within 60 days before the index date; recent users, with the most recent prescription filled 61–180 days before the index date; and never users, with no record of dispensed inhaled or oral corticosteroids in the prescription database before the index date. Within the category of current users, we singled out new users, whose first recorded prescription of inhaled or oral corticosteroids was dispensed within 60 days before the index date.

Potential confounders
From the DNRP, we obtained information about maternal diagnoses of diseases typically treated with corticosteroids, ie, asthma, rheumatoid arthritis, and inflammatory bowel disease, recorded from 1977 until delivery. We identified history of diabetes or epilepsy before the index date using discharge diagnoses from hospital admissions or outpatient/emergency visits or by prescriptions redeemed for antidiabetic or antiepileptic drugs. Both diseases have been associated with an increased risk of miscarriage. For the same reason, we obtained data on women’s prescriptions for nonsteroidal anti-inflammatory drugs (NSAIDs) redeemed
within 12 weeks before the index date.21 All relevant diagnostic and drug codes are listed in Supplementary Table 1.

Statistical analysis
We summarized the demographic characteristics and medical history of cases and controls. We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between corticosteroid use and risk of miscarriage, separately for oral and inhaled preparations, and adjusting for age, past medical history of diabetes and epilepsy, and NSAID use. We then examined the association of corticosteroid use separately for early and late miscarriages.

Finally, we conducted a series of sensitivity analyses. We examined whether variation in the definition of corticosteroid exposure affected the results by extending the definition of current and new use from 60 days to 90 days before the index date. We then recalculated ORs after excluding cases and controls with a history of induced abortion in order to examine the impact of previous pregnancy loss. We used SAS® version 9.2 software for all analyses (SAS Institute, Cary, NC, USA). This study was approved by the Danish Data Protection Agency (2003-41-3103).
Table 2 Use of inhaled and oral corticosteroids and miscarriage among women in northern Denmark, 1997–2009

<table>
<thead>
<tr>
<th>Corticosteroid use</th>
<th>Case/control ratio Unadjusted OR (95% CI)</th>
<th>Adjusted OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids overall</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>165/147</td>
<td>1.15 (0.97–1.35)</td>
</tr>
<tr>
<td>Recent</td>
<td>118/1286</td>
<td>0.92 (0.76–1.12)</td>
</tr>
<tr>
<td>Former</td>
<td>976/9,213</td>
<td>1.07 (1.00–1.14)</td>
</tr>
<tr>
<td>Never</td>
<td>9,768/98,291</td>
<td>Reference</td>
</tr>
<tr>
<td>New</td>
<td>19/245</td>
<td>0.78 (0.49–1.25)</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>140/1,143</td>
<td>1.23 (1.03–1.47)</td>
</tr>
<tr>
<td>Recent</td>
<td>87/907</td>
<td>0.95 (0.76–1.19)</td>
</tr>
<tr>
<td>Former</td>
<td>575/5,496</td>
<td>1.05 (0.96–1.15)</td>
</tr>
<tr>
<td>Never</td>
<td>10,172/102,194</td>
<td>Reference</td>
</tr>
<tr>
<td>New</td>
<td>9/95</td>
<td>0.92 (0.46–1.82)</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>28/341</td>
<td>0.82 (0.56–1.21)</td>
</tr>
<tr>
<td>Recent</td>
<td>35/411</td>
<td>0.85 (0.60–1.21)</td>
</tr>
<tr>
<td>Former</td>
<td>474/4,387</td>
<td>1.08 (0.98–1.19)</td>
</tr>
<tr>
<td>Never</td>
<td>10,437/104,601</td>
<td>Reference</td>
</tr>
<tr>
<td>New</td>
<td>9/171</td>
<td>0.60 (0.32–1.14)</td>
</tr>
</tbody>
</table>

Note: *Adjusted for age at index date, history of diabetes and epilepsy, and use of NSAIDs 12 weeks before the index date.

Abbreviations: OR, odds ratio; CI, confidence interval; NSAIDs, nonsteroidal anti-inflammatory drugs.

and 0.4% among the controls (adjusted OR 0.74; 95% CI 0.52–1.05). Excluding 1,585 cases (14.4%) and 13,197 controls (12.0%) with a record of induced abortion did not change the interpretation of the overall results (data available on request).

Discussion

In this large population-based, case-control study, current use of inhaled corticosteroids was associated with a slightly increased risk of miscarriage during the first 12 weeks of gestation as compared with no recorded use. There was no evidence of an association between use of oral corticosteroids and risk of miscarriage.

Our study extends earlier research by including information on gestational age at miscarriage. Because the etiology of miscarriage varies according to gestational age,22 an association between corticosteroid exposure and early but not late miscarriage is an important finding. An early miscarriage may represent fetal loss secondary to malformation incompatible with fetal survival. Studies of maternal use of inhaled and oral corticosteroids in early gestation and risk of congenital malformations in offspring have been inconclusive.4,6,10,11,23–30

Selection bias arising from early-gestation miscarriage of malformed embryos could explain the lack of an apparent association, if such an association exists.31,32

Presence of an association with miscarriage for inhaled but not oral corticosteroids is counterintuitive. Oral corticosteroids reach higher concentrations in the maternal circulation3 and therefore could be expected to lead to higher levels of fetal exposure. An abnormal maternal immune response has been assumed to act as an initiator of miscarriage.22,31 The anti-inflammatory effect of corticosteroids might protect against this if given in high doses. In fact, high doses of corticosteroids are used to prevent recurrent miscarriages,34 although the effectiveness of this treatment is still controversial.34–36

The association observed for inhaled corticosteroids may be due to confounding by asthma,37 because asthma is a common indication for inhaled corticosteroids. Asthma exacerbations induce hypoxia and may induce...
abnormal smooth muscle activity in the uterus, similar to airway smooth muscle contractions, and therefore could be a risk factor for miscarriage.30,38,39 Although prevalence of asthma diagnoses between cases and controls did not differ substantially in our study, there could be residual confounding by asthma not leading to hospital contact37 and therefore not measured in our study.

Our study corroborates a large prevalence study based on The Health Improvement Network in the United Kingdom of almost 300,000 pregnancies. It was conducted to quantify risks of major adverse pregnancy outcomes and obstetric complications in women with and without asthma. The study reported a higher risk of miscarriage (adjusted OR 1.24; 95% CI 1.17–1.34) among women who used inhaled corticosteroids compared with women who did not, after controlling for age, smoking, and body mass index.9 Similarly, a cohort study based on data from an international asthma trial reported an unadjusted relative risk for miscarriage of 1.25 (95% CI 0.63–2.47), comparing users (n = 196) and nonusers (n = 117) of inhaled corticosteroids.9 A Canadian study based on the Motherisk Program, in which pregnant women voluntarily report information relevant to fetal safety after drug use in pregnancy, found no increased risk of miscarriage (unadjusted relative risk 1.01; 95% CI 0.48–2.11) among users of oral corticosteroids (n = 187) during pregnancy compared with nonusers (n = 188),11 which is in line with our findings. In contrast, an Israeli study reported an unadjusted relative risk of 1.66 (95% CI 1.12–2.48) for miscarriage among oral corticosteroid users (n = 311) compared with nonusers (n = 790).10 However, because this study was based on data reported to a teratogen information service, the results could be susceptible to overestimation due to self-referral bias.40

In summary, all the evidence taken together indicates that an association with miscarriage, if it exists, seems to be restricted to inhaled corticosteroids.

Our study was population-based, and we identified cases and controls from a larger background population than earlier studies.8,10,11 We had access to complete independent registration of births, miscarriages, and prescriptions, which reduced the risk of selection and information biases. Availability of information on gestational age at miscarriage allowed us to select controls at the gestational period during which they were eligible to become cases and to ascertain corticosteroid use in the same preceding gestational period for both cases and controls. Finally, animal studies have suggested that corticosteroids reduce fetal growth.41 Therefore, corticosteroids could theoretically affect the gestational age determined by ultrasound, creating an appearance that corticosteroid-affected miscarriages occur earlier in gestation than they actually do.

We identified occurrence of miscarriage from hospital-based diagnoses. The estimated positive predictive value of miscarriage diagnoses recorded in the DNRP is 97%.42 Still, data may be incomplete because some women with very early miscarriage do not seek medical contact or hospitalization and are thus not registered.32 An estimated 25% of spontaneous abortions reported by women are not registered in the DNRP.43

Information on use of corticosteroids was based on prescriptions redeemed before the occurrence of miscarriage. However, redeemed prescriptions do not fully reflect the timing of drug intake and do not include corticosteroid use during hospitalizations. Such errors are unlikely to differ by miscarriage status; as a result, estimates of association may be diluted.44

We were able to take age, history of diabetes and epilepsy, use of NSAIDs, and underlying disease into account in our analysis. Although none of these factors affected our estimates noticeably, unmeasured confounding cannot be ruled out in observational studies. Generally, the data sources used for this study, as is common for routine administrative registries, do not contain information on smoking, alcohol, body mass index, or caffeine intake. Smoking is associated with an increased risk of miscarriage.45,46 A Danish prevalence study of 832,636 live births from 1996 to 2008, with data on maternal smoking recorded in the Medical Birth Registry, reported that 18.2% of women who used corticosteroids in the first trimester smoked compared with 19.5% of nonusers.49 Thus, a positive association between corticosteroids and miscarriage is unlikely to be explained by smoking. Although our study population was larger than that in most other studies, the number of informative observations in our dataset was low in some subgroups. Therefore, some of our estimates are imprecise.

Although physicians always need to be cautious when giving medical treatment to pregnant women, not treating pregnant women could also put both mother and fetus at risk.47 For example, untreated asthma has been associated with an increased risk of maternal morbidity, eg, exacerbations.48 The evidence from our study is not sufficient to warrant discontinuation of treatment with inhaled corticosteroids during pregnancy.

In conclusion, our results suggest a slightly increased risk of early miscarriage among women who were current users of inhaled corticosteroids but explanations alternative to causal ones cannot be ruled out.
Acknowledgments
This work was supported in part by grants from the Augustinus Foundation, the Foundation of Dagmar Marshalls, the Foundation of the Faculty of Health in the Central Region of Denmark, the Foundation of Sophus Jacobsen and Astrid Jacobsen, the Department of Clinical Epidemiology Research, and Aarhus University.

Disclosure
The authors report no conflicts of interest in this work.

References


### Supplementary Table 1

Codes from the International Classification of Diseases (ICD) and Anatomical Therapeutic Chemical (ATC) classification used to identify diagnoses from the Danish National Registry of Patients and to identify dispensing of prescribed drugs from the Aarhus University Prescription Database.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>ICD-8 codes</th>
<th>ICD-10 codes</th>
<th>ATC codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscarriage</td>
<td>643</td>
<td>O02–O03</td>
<td></td>
</tr>
<tr>
<td>Induced abortion</td>
<td>640, 641, 642</td>
<td>O04</td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>493</td>
<td>J45–J46</td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>712.19, 712.39, 712.59</td>
<td>M05–M06</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>563.00, 563.01, 563.10, 569.02</td>
<td>K51–K50</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>250</td>
<td>E10–E14</td>
<td></td>
</tr>
<tr>
<td>Epilepsy</td>
<td>345</td>
<td>G40</td>
<td></td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td></td>
<td></td>
<td>R03BA01, R03BA02, R03BA05, R03BA07, R03AK06, R03AK07</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
<td></td>
<td></td>
<td>H02AB04, H02AB06, H02AB07, H02AB09</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory drugs</td>
<td></td>
<td></td>
<td>M01A</td>
</tr>
<tr>
<td>Antidiabetics</td>
<td></td>
<td></td>
<td>A10</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td></td>
<td></td>
<td>N03A</td>
</tr>
</tbody>
</table>